March 29, 2017 / 2:34 PM / 5 months ago

BRIEF-Glenmark Pharmaceuticals reports positive results from phase 3 trial of gsp 301

March 29 (Reuters) - Glenmark Pharmaceuticals Ltd

* Glenmark Pharmaceuticals reports positive results from a Phase 3 trial of GSP 301, Mometasone/Olopatadine fixed-dose combination nasal spray, in seasonal allergic rhinitis

* In trial treatment with GSP 301 demonstrated statistically significant and clinically meaningful improvement from baseline

* All investigational treatments administered in trial were well-tolerated Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below